eLife (Nov 2022)
EROS is a selective chaperone regulating the phagocyte NADPH oxidase and purinergic signalling
- Lyra O Randzavola,
- Paige M Mortimer,
- Emma Garside,
- Elizabeth R Dufficy,
- Andrea Schejtman,
- Georgia Roumelioti,
- Lu Yu,
- Mercedes Pardo,
- Kerstin Spirohn,
- Charlotte Tolley,
- Cordelia Brandt,
- Katherine Harcourt,
- Esme Nichols,
- Mike Nahorski,
- Geoff Woods,
- James C Williamson,
- Shreehari Suresh,
- John M Sowerby,
- Misaki Matsumoto,
- Celio XC Santos,
- Cher Shen Kiar,
- Subhankar Mukhopadhyay,
- William M Rae,
- Gordon J Dougan,
- John Grainger,
- Paul J Lehner,
- Michael A Calderwood,
- Jyoti Choudhary,
- Simon Clare,
- Anneliese Speak,
- Giorgia Santilli,
- Alex Bateman,
- Kenneth GC Smith,
- Francesca Magnani,
- David C Thomas
Affiliations
- Lyra O Randzavola
- ORCiD
- Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom
- Paige M Mortimer
- Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom
- Emma Garside
- Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom
- Elizabeth R Dufficy
- The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
- Andrea Schejtman
- Molecular Immunology Unit, UCL Great Ormond Street Institute of Child Health, London, United Kingdom
- Georgia Roumelioti
- Functional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
- Lu Yu
- Functional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
- Mercedes Pardo
- Functional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
- Kerstin Spirohn
- Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, United States; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, United States; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
- Charlotte Tolley
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Cordelia Brandt
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Katherine Harcourt
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Esme Nichols
- Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom
- Mike Nahorski
- Cambridge Institute of Medical Research, University of Cambridge, Cambridge, United Kingdom
- Geoff Woods
- Cambridge Institute of Medical Research, University of Cambridge, Cambridge, United Kingdom
- James C Williamson
- The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, United Kingdom
- Shreehari Suresh
- The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
- John M Sowerby
- The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, United Kingdom
- Misaki Matsumoto
- Department of Pharmacology, Kyoto Prefectural University of Medicine, Kyoto, Japan
- Celio XC Santos
- School of Cardiovascular Medicine and Sciences, James Black Centre, King's College London, London, United Kingdom
- Cher Shen Kiar
- Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom
- Subhankar Mukhopadhyay
- Peter Gorer Department of Immunobiology, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom
- William M Rae
- The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, United Kingdom
- Gordon J Dougan
- The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
- John Grainger
- Functional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom; Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom
- Paul J Lehner
- ORCiD
- The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, United Kingdom
- Michael A Calderwood
- Center for Cancer Systems Biology (CCSB), Dana-Farber Cancer Institute, Boston, United States; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, United States; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
- Jyoti Choudhary
- Functional Proteomics, Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
- Simon Clare
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Anneliese Speak
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom
- Giorgia Santilli
- Molecular Immunology Unit, UCL Great Ormond Street Institute of Child Health, London, United Kingdom
- Alex Bateman
- ORCiD
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom
- Kenneth GC Smith
- The Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus, Cambridge, United Kingdom
- Francesca Magnani
- ORCiD
- Department of Biology and Biotechnology, University of Pavia, Pavia, Italy
- David C Thomas
- ORCiD
- Department of Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom
- DOI
- https://doi.org/10.7554/eLife.76387
- Journal volume & issue
-
Vol. 11
Abstract
EROS (essential for reactive oxygen species) protein is indispensable for expression of gp91phox, the catalytic core of the phagocyte NADPH oxidase. EROS deficiency in humans is a novel cause of the severe immunodeficiency, chronic granulomatous disease, but its mechanism of action was unknown until now. We elucidate the role of EROS, showing it acts at the earliest stages of gp91phox maturation. It binds the immature 58 kDa gp91phox directly, preventing gp91phox degradation and allowing glycosylation via the oligosaccharyltransferase machinery and the incorporation of the heme prosthetic groups essential for catalysis. EROS also regulates the purine receptors P2X7 and P2X1 through direct interactions, and P2X7 is almost absent in EROS-deficient mouse and human primary cells. Accordingly, lack of murine EROS results in markedly abnormal P2X7 signalling, inflammasome activation, and T cell responses. The loss of both ROS and P2X7 signalling leads to resistance to influenza infection in mice. Our work identifies EROS as a highly selective chaperone for key proteins in innate and adaptive immunity and a rheostat for immunity to infection. It has profound implications for our understanding of immune physiology, ROS dysregulation, and possibly gene therapy.
Keywords